Creative Biolabs Launches Enhanced mRNA Platform for Therapeutics and iPSC Reprogramming

Creative Biolabs has announced a major upgrade to its mRNA technology platform, offering an integrated end-to-end solution spanning design, delivery, and functional validation while extending applications into induced pluripotent stem cell reprogramming. The enhanced platform creates new opportunities for regenerative medicine and cell-based therapies as mRNA technologies continue expanding across gene therapy, cancer vaccines, and cell therapy applications.

The platform's in silico mRNA structural prediction capability enables detailed analysis of mRNA secondary structures and three-dimensional conformations using computational modeling, dynamic programming algorithms, and nearest-neighbor free-energy rules. This service supports multiple sequence alignment, conserved structure identification, primer design, and promoter analysis, empowering researchers to optimize mRNA constructs from the earliest stages of molecular design. The system can function independently or support other mRNA development workflows, providing crucial structural insights for therapeutic optimization.

At the delivery level, Creative Biolabs provides customized polymer development services through polyplex formation. By complexing cationic polymers such as polyethyleneimine and PDMAEMA with mRNA molecules, the platform generates nanoscale polyplexes with enhanced stability and high cellular uptake efficiency. The team adjusts polymer type, molecular weight, geometry, and N/P ratios to optimize carrier performance, significantly improving mRNA stability in vivo and promoting efficient intracellular release. These polyplex systems serve as critical enablers for mRNA therapeutics including gene therapy and protein replacement applications.

Beyond therapeutic applications, Creative Biolabs has adapted its mRNA platform to iPSC reprogramming using a self-developed mRNA-based service that is non-integrative and footprint-free. The approach sustains expression of reprogramming factors OCT4, SOX2, KLF4, and GLIS1 through repeated mRNA transfection, generating induced pluripotent stem cells with high efficiency while eliminating genomic integration risks associated with viral vectors. This method is both safe and highly scalable, supporting cell quantities ranging from millions to billions, making it suitable for large-scale regenerative medicine applications.

The integration of structure-level design, optimized polymeric delivery, and mRNA-driven cell reprogramming provides clients with a unified and streamlined mRNA development pathway. This comprehensive approach accelerates projects from early construct optimization to functional demonstration, positioning Creative Biolabs to support a wide spectrum of pharmaceutical, biotechnology, and academic programs worldwide as mRNA technologies continue their rapid development across multiple therapeutic domains.